[go: up one dir, main page]

DK0717987T3 - Suspension-aerosol-formuleringer - Google Patents

Suspension-aerosol-formuleringer

Info

Publication number
DK0717987T3
DK0717987T3 DK96200109T DK96200109T DK0717987T3 DK 0717987 T3 DK0717987 T3 DK 0717987T3 DK 96200109 T DK96200109 T DK 96200109T DK 96200109 T DK96200109 T DK 96200109T DK 0717987 T3 DK0717987 T3 DK 0717987T3
Authority
DK
Denmark
Prior art keywords
aerosol formulations
suspension aerosol
aerosol formulation
amount
hfc134a
Prior art date
Application number
DK96200109T
Other languages
Danish (da)
English (en)
Inventor
Robert K Schultz
David W Schultz
Martin J Oliver
Robert A Moris
Philip A Jinks
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0717987(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of DK0717987T3 publication Critical patent/DK0717987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
DK96200109T 1991-12-18 1992-12-11 Suspension-aerosol-formuleringer DK0717987T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81040191A 1991-12-18 1991-12-18
US80979191A 1991-12-18 1991-12-18
US87803992A 1992-05-04 1992-05-04

Publications (1)

Publication Number Publication Date
DK0717987T3 true DK0717987T3 (da) 2001-11-12

Family

ID=27420051

Family Applications (3)

Application Number Title Priority Date Filing Date
DK96200109T DK0717987T3 (da) 1991-12-18 1992-12-11 Suspension-aerosol-formuleringer
DK93901414.8T DK0617610T3 (da) 1991-12-18 1992-12-11 Suspensionsaerosolformuleringer.
DK00123885T DK1086688T3 (da) 1991-12-18 1992-12-11 Aerosolformuleringer til suspensioner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK93901414.8T DK0617610T3 (da) 1991-12-18 1992-12-11 Suspensionsaerosolformuleringer.
DK00123885T DK1086688T3 (da) 1991-12-18 1992-12-11 Aerosolformuleringer til suspensioner

Country Status (13)

Country Link
US (2) US6743413B1 (fr)
EP (3) EP1086688B1 (fr)
JP (2) JP3908269B2 (fr)
AT (3) ATE260641T1 (fr)
AU (2) AU675633B2 (fr)
CA (2) CA2320129C (fr)
DE (3) DE69233319T2 (fr)
DK (3) DK0717987T3 (fr)
ES (3) ES2099415T3 (fr)
GR (2) GR3022874T3 (fr)
NZ (1) NZ246421A (fr)
PT (2) PT717987E (fr)
WO (1) WO1993011747A1 (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226067T1 (de) 1991-06-10 2002-11-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
ATE171865T1 (de) * 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
NZ246421A (en) * 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
CA2178473C (fr) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Compositions d'aerosols a base de flunisolide
AU709783B2 (en) * 1994-03-14 1999-09-09 Abbott Laboratories Aerosol drug formulations containing vitamin E
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
EP0810853B1 (fr) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols contenant des dispersions de nanoparticules
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) † 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) † 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
EP1102579B1 (fr) * 1998-08-04 2003-03-19 Jago Research Ag Formulations d'aerosol a usage medical
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
EP1121112B1 (fr) * 1998-10-17 2002-06-05 Boehringer Ingelheim Pharma KG Concentre stable de formoterol
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
DE19924098A1 (de) * 1999-05-26 2000-12-07 Boehringer Ingelheim Pharma Edelstahlkanister für treibgasbetriebene Dosieraerosole
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
GB9924808D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Medicament dispenser
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
EP1345629A2 (fr) 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particules a liberation prolongee destinees a etre inhalees
ATE267591T1 (de) 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2465675C (fr) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Compositions particulaires ameliorees destinees a etre administrees par voie pulmonaire
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
PT1572622E (pt) 2002-12-10 2006-08-31 Sepracor Inc Sal de levalbuterol
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
JP2006527237A (ja) * 2003-06-13 2006-11-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ホルモテロールと及びシクレソニドの組合せ物
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US20050123484A1 (en) * 2003-10-02 2005-06-09 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1595531A1 (fr) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20050255048A1 (en) * 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
CA2581999C (fr) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation de formulations d'aerosol
EP1949891A1 (fr) 2004-10-12 2008-07-30 Generics (UK) Limited Procédé pour la préparation de formules à suspension pour aérosol, caractérisé en ce que les particles soient formées par précipitation à l'intérieur d'un récipient
WO2007008427A2 (fr) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Compositions aerosol et procedes
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20080112886A1 (en) * 2006-09-08 2008-05-15 The Regents Of The University Of California Engineering shape of polymeric micro- and nanoparticles
US7754096B2 (en) * 2007-02-01 2010-07-13 E.I. Du Pont De Nemours And Company Liquefied-gas aerosol dusting composition containing denatonium benzoate
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009137819A1 (fr) 2008-05-09 2009-11-12 Innovative Pulmonary Solutions, Inc. Systèmes, ensembles et procédés utilisables pour le traitement d'un arbre bronchique
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
PL2987490T3 (pl) 2009-07-15 2017-12-29 Theravance Biopharma R&D Ip, Llc Postacie krystaliczne wolnej zasady związku bifenylowego
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
CN104042322B (zh) 2009-10-27 2017-06-06 赫莱拉公司 具有可冷却的能量发射组件的递送装置
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CA2780608C (fr) 2009-11-11 2019-02-26 Innovative Pulmonary Solutions, Inc. Systemes, appareils et procedes pour traiter un tissu et controler une stenose
US20110124589A1 (en) 2009-11-24 2011-05-26 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
CA2793170C (fr) 2010-03-15 2018-04-17 Virginia Commonwealth University Dapsone aerosolisee en tant que therapie contre l'inflammation des voies respiratoires et l'anomalie du transport mucociliaire
AU2011253203A1 (en) 2010-05-10 2012-11-22 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2011143106A1 (fr) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Composés pyrazolopyridiniques bifonctionnels
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2012083178A1 (fr) 2010-12-17 2012-06-21 Neo Oncology Inc. Procédés et dispositifs pour l'utilisation d'alcool isoperillylique
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
DK2855435T3 (en) 2012-05-29 2018-07-16 Parion Sciences Inc DENDRIMER-LIKE AMINOAMIDES WITH SODIUM CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF DRY EYES AND OTHER MILK DISEASES
US9012490B2 (en) * 2012-08-17 2015-04-21 Howard University Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
BR112015014349A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
US9394314B2 (en) 2012-12-21 2016-07-19 Map Pharmaceuticals, Inc. 8′-hydroxy-dihydroergotamine compounds and compositions
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
CN107613768B (zh) 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (fr) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (fr) 1957-01-31 1957-04-11
BE629985A (fr) 1962-11-29
US3320125A (en) 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3809294A (en) 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3897779A (en) 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
FI770215A7 (fr) 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
JPS5325284A (en) 1976-08-19 1978-03-08 Daikin Ind Ltd Aerosol composition
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
CA1201114A (fr) 1980-02-15 1986-02-25 Gordon H. Phillipps Carbothioates d'androstane
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
ATE3774T1 (de) 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
US4311863A (en) 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
JPS60224638A (ja) 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
US4851595A (en) 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5206268A (en) 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828544D0 (en) 1988-12-07 1989-01-11 Ici Plc Chemical process
DE3905726A1 (de) 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
US4945119A (en) 1989-05-10 1990-07-31 The Dow Chemical Company Foaming system for rigid urethane and isocyanurate foams
US4940171A (en) 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
AU633584B2 (en) 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5254755A (en) 1990-12-04 1993-10-19 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5182040A (en) 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
ATE226067T1 (de) 1991-06-10 2002-11-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
SK140493A3 (en) 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
AU2178392A (en) * 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ES2079210T3 (es) 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
NZ246421A (en) * 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
GB9200148D0 (en) * 1992-01-06 1992-02-26 Minnesota Mining & Mfg Aerosol valves
US5202110A (en) 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5314682A (en) 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
CA2178473C (fr) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Compositions d'aerosols a base de flunisolide
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations

Also Published As

Publication number Publication date
DE69233319T2 (de) 2005-02-17
EP0717987B1 (fr) 2001-08-29
CA2320129C (fr) 2003-02-11
WO1993011747A1 (fr) 1993-06-24
AU709052B2 (en) 1999-08-19
AU709052C (en) 2002-04-11
AU3272893A (en) 1993-07-19
EP1086688B1 (fr) 2004-03-03
JP3908269B2 (ja) 2007-04-25
JP2004143183A (ja) 2004-05-20
DE69232034T2 (de) 2002-06-06
EP0617610A1 (fr) 1994-10-05
DK0617610T3 (da) 1997-10-06
JPH07502275A (ja) 1995-03-09
DE69233319D1 (de) 2004-04-08
GR3036467T3 (en) 2001-11-30
DE69232034D1 (de) 2001-10-04
EP0717987A2 (fr) 1996-06-26
CA2126244C (fr) 2000-09-26
ATE204743T1 (de) 2001-09-15
CA2126244A1 (fr) 1993-06-24
AU675633B2 (en) 1997-02-13
DE69218455T2 (de) 1997-10-23
CA2320129A1 (fr) 1993-06-24
GR3022874T3 (en) 1997-06-30
EP0717987A3 (fr) 1996-07-03
ATE260641T1 (de) 2004-03-15
PT717987E (pt) 2001-12-28
ES2099415T3 (es) 1997-05-16
ES2159678T3 (es) 2001-10-16
US6743413B1 (en) 2004-06-01
DE69218455D1 (de) 1997-04-24
DK1086688T3 (da) 2004-08-16
AU1234297A (en) 1997-03-20
EP0617610B1 (fr) 1997-03-19
ES2216800T3 (es) 2004-11-01
NZ246421A (en) 1996-05-28
ATE150296T1 (de) 1997-04-15
PT1086688E (pt) 2004-06-30
US20040197273A1 (en) 2004-10-07
EP1086688A1 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
DK0717987T3 (da) Suspension-aerosol-formuleringer
DK0553298T3 (da) Aerosolformulering omfattende beclomethason-17,21-dipropionat
ATE134509T1 (de) Fluorchlorkohlenwasserstoffreie aerosolformulierungen
EP1277467A3 (fr) Formulations d' aérosols sans chlorofluorohydrocarbures
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav